One-liner#

Risk-stratify palpitations to identify arrhythmias requiring urgent intervention, then efficiently evaluate and manage benign causes (ectopy, sinus tachycardia, anxiety) without over-monitoring low-risk patients.

Quick nav#

• Red flags / send to ED
• Key history
• Focused exam
• Differential (quick pattern recognition)
• Workup
• Initial management
• Management by diagnosis
• Follow-up
• Patient instructions
• Smartphrase snippets

Red flags / send to ED#

• Palpitations with syncope, presyncope, or near-collapse
• Associated chest pain concerning for ACS
• Palpitations with dyspnea, hypoxia, or signs of heart failure
• Hemodynamic instability: hypotension, altered mental status, poor perfusion
• Known structural heart disease (HCM, severe valvular disease, prior MI with reduced EF) with new sustained palpitations
• Wide-complex tachycardia on ECG
• HR >150 with symptoms or inability to control rate
• Family history of sudden cardiac death + exertional palpitations

Key history#

Characterize the palpitations:

• Onset/offset: sudden (SVT, VT) vs gradual (sinus tachycardia, anxiety)
• Duration: seconds (ectopy) vs minutes-hours (SVT, AF) vs continuous
• Regularity: regular (SVT, sinus tach, VT) vs irregular (AF, ectopy, MAT)
• Rate: “fast” vs “skipped beats” vs “pounding”
• Patient maneuvers: does bearing down or cold water stop it? (vagal → SVT)

Triggers and context:

• Exertion, caffeine, alcohol, dehydration, sleep deprivation
• Stress, anxiety, panic symptoms
• Position (lying down → ectopy more noticeable)
• Medications: stimulants, decongestants, bronchodilators, thyroid hormone
• Supplements: energy drinks, pre-workout, weight loss supplements

Associated symptoms:

• Chest pain, dyspnea, lightheadedness, syncope (concerning)
• Polyuria after episode (SVT releases ANP)
• Anxiety, paresthesias, hyperventilation (panic)

Risk factors for significant arrhythmia:

• Structural heart disease: prior MI, cardiomyopathy, valvular disease, CHD
• Family history: sudden cardiac death <50, HCM, long QT, Brugada, ARVC
• Prior arrhythmia or ablation
• Electrolyte abnormalities, thyroid disease

Focused exam#

• Vitals: HR (rate and regularity), BP, O2 sat
• General: anxiety level, diaphoresis, tremor
• Cardiac: irregular rhythm, murmurs (MVP, AS, HCM), S3 (HF), JVD
• Thyroid: enlargement, nodules, tremor, lid lag
• Pulmonary: wheezes (bronchodilator use), crackles (HF)
• Extremities: edema (HF), tremor (hyperthyroid, anxiety)

If palpitations occurring during visit:

• Obtain ECG immediately
• Check if regular vs irregular, narrow vs wide complex
• Attempt vagal maneuvers if stable SVT

Differential (quick pattern recognition)#

Common/likely (outpatient)#

Can’t-miss / urgent#

Workup#

All patients:

• ECG: look for arrhythmia, delta wave (WPW), prolonged QT, signs of structural disease (Q waves, LVH, RBBB/LBBB)
• Basic labs: TSH, CBC (anemia), BMP (electrolytes, renal function)

Extended workup based on risk:

When NOT to monitor:

• Classic anxiety-related palpitations with normal ECG, no risk factors, no syncope
• Clearly caffeine/stimulant-related that resolves with avoidance
• Rare, brief “skipped beats” in young healthy patient with normal ECG
• Monitoring is unlikely to change management if you’ve already decided the patient is low-risk

When NOT to order echo:

• Young patient with brief ectopy, normal ECG, no murmur, no family history of SCD or cardiomyopathy
• Clearly anxiety-related palpitations with normal exam and ECG

Initial management#

• Reassurance is treatment for benign ectopy and anxiety-related palpitations
• Trigger avoidance: caffeine, alcohol, stimulants, decongestants, sleep deprivation
• Treat underlying cause: anemia, hyperthyroidism, dehydration, anxiety
• If AF identified: rate control + CHA₂DS₂-VASc assessment for anticoagulation
• If concerning features: expedite monitoring and/or cardiology referral

Management by diagnosis#

Premature beats (PACs/PVCs)#

Education:

• Extremely common; almost everyone has them
• Not dangerous in structurally normal hearts
• Often more noticeable at rest; exercise typically suppresses them
• Caffeine, alcohol, stress, and sleep deprivation can increase frequency

Treatment:

First-line: reassurance and trigger avoidance

If frequent and symptomatic (>10% PVC burden or significantly bothersome):

Referral considerations:

• PVC burden >15–20%: risk of PVC-induced cardiomyopathy; consider EP referral for ablation
• Symptomatic despite medical therapy: EP referral

Follow-up: 4–6 weeks if started on medication; otherwise PRN. Echo if high PVC burden to assess LV function.

Sinus tachycardia#

Education:

• Sinus tachycardia is a symptom, not a diagnosis—find the cause
• Common causes: anxiety, dehydration, anemia, infection, hyperthyroidism, medications, deconditioning
• Treatment is addressing the underlying cause, not suppressing the heart rate

Treatment:

Treat underlying cause:

• Dehydration → fluids
• Anemia → iron, workup
• Hyperthyroidism → treat thyroid disease
• Anxiety → see anxiety management
• Medication-induced → adjust offending agent

Inappropriate sinus tachycardia (IST) or POTS—if confirmed by specialist:

Follow-up: Based on underlying cause. IST/POTS typically managed with cardiology or autonomic specialist.

Atrial fibrillation#

Education:

• AF is the most common sustained arrhythmia; risk increases with age
• Two goals: (1) control symptoms with rate or rhythm control, (2) prevent stroke with anticoagulation
• Stroke risk is based on CHA₂DS₂-VASc score, not on symptoms or AF burden
• Lifestyle factors matter: weight loss, alcohol reduction, OSA treatment, BP control

Treatment:

Rate control (first-line for most patients):

Anticoagulation (based on CHA₂DS₂-VASc):

Bleeding risk (HAS-BLED): Use to identify modifiable bleeding risks, NOT to withhold anticoagulation. Score ≥3 = high bleeding risk; address modifiable factors (uncontrolled HTN, labile INR, alcohol, unnecessary ASA/NSAIDs) but still anticoagulate if CHA₂DS₂-VASc indicates.

Starting anticoagulation:

• Can start DOAC same day as diagnosis in most patients
• Echo is NOT required before starting anticoagulation (but should be obtained to assess LA size, LV function, and valvular disease)
• If patient already on anticoagulation for VTE: continue current regimen; no need to change unless subtherapeutic

Rhythm control considerations:

• Consider if: symptomatic despite rate control, younger patient, HFrEF, patient preference
• Refer to cardiology/EP for antiarrhythmic drugs or ablation
• Cardioversion timing: If AF duration >48 hours or unknown, need 3+ weeks of anticoagulation OR TEE to rule out LA thrombus before cardioversion. If <48 hours and hemodynamically stable, can cardiovert with anticoagulation started before procedure.

Rate control targets:

• General: HR <110 at rest (lenient control is acceptable for most)
• HFrEF: May benefit from stricter control (HR <80); beta-blockers preferred
• Symptomatic despite lenient control: Target HR <80

Follow-up: 2–4 weeks after starting rate control; ensure anticoagulation adherence. Cardiology referral for rhythm control consideration, ablation, or complex cases.

Atrial flutter#

Education:

• Atrial flutter is a “cousin” of AF—similar stroke risk, similar rate control approach
• Classic flutter has a regular ventricular rate (often ~150 bpm with 2:1 block)
• Unlike AF, flutter is highly amenable to ablation (>90% success with cavotricuspid isthmus ablation)
• Anticoagulation approach is identical to AF (same CHA₂DS₂-VASc thresholds)

Treatment:

Rate control:

• Same agents as AF (beta-blockers, CCBs, digoxin)
• Flutter is often harder to rate-control than AF; may need higher doses or combination therapy
• Target HR <110 at rest (same as AF)

Anticoagulation:

• Same as AF: Use CHA₂DS₂-VASc score; same thresholds for anticoagulation
• Do not withhold anticoagulation because “it’s just flutter”—stroke risk is equivalent

Rhythm control:

• Ablation is first-line for rhythm control in flutter (more effective than antiarrhythmics)
• Cavotricuspid isthmus ablation: >90% success, low risk
• Many patients with flutter also have or will develop AF; discuss with EP

Key distinction from AF:

• Flutter is regular (AF is irregularly irregular)
• Flutter often presents at ~150 bpm (2:1 block) or ~100 bpm (3:1 block)
• ECG shows “sawtooth” flutter waves (best seen in II, III, aVF)
• Ablation is more straightforward and effective for flutter than AF

Follow-up: EP referral for ablation consideration. If managing medically, same follow-up as AF.

SVT (AVNRT, AVRT, atrial tachycardia)#

Education:

• SVT is usually not dangerous but can be very symptomatic
• Episodes can often be terminated with vagal maneuvers (bearing down, cold water on face)
• Definitive treatment is catheter ablation (>95% success rate for AVNRT/AVRT)

Treatment:

Acute termination (if captured in office and stable):

• Vagal maneuvers: Valsalva (modified: blow into syringe then lie flat with legs raised), carotid massage (if no bruit), cold water to face
• If vagal maneuvers fail and patient stable: adenosine 6 mg rapid IV push → 12 mg if no response (requires IV access and monitoring)

Chronic management:

Ablation:

• Refer to EP for ablation if: frequent episodes, symptomatic despite meds, patient prefers definitive treatment, medication intolerance
• AVNRT/AVRT ablation success >95% with low complication rate

WPW-specific considerations:

• If WPW with AF: DO NOT give AV nodal blockers (beta-blockers, CCBs, digoxin, adenosine)—can cause preferential conduction down accessory pathway → VF
• Safe options for WPW + AF: procainamide, ibutilide (in monitored setting); immediate EP/cardiology consultation
• All WPW patients should be referred to EP for ablation evaluation (curative, prevents sudden death risk)
• Asymptomatic WPW with delta wave: still refer to EP for risk stratification

Follow-up: Cardiology/EP referral for most patients. If managing medically, follow up 4–6 weeks after starting therapy.

Anxiety-related palpitations#

Education:

• Anxiety causes real physical symptoms including palpitations, chest tightness, and shortness of breath
• The heart is structurally normal; these symptoms are not dangerous
• Avoiding triggers often makes anxiety worse; treatment is effective

Treatment:

Acute:

• Reassurance after appropriate cardiac risk stratification
• Breathing techniques (slow diaphragmatic breathing)
• Reduce caffeine, stimulants

Chronic (if recurrent or meets criteria for anxiety disorder):

Follow-up: 2–4 weeks after starting medication. Consider CBT referral.

Smartwatch/consumer device-detected arrhythmias#

Education:

• Consumer devices (Apple Watch, Fitbit, Kardia) can detect irregular rhythms but have limitations
• False positives are common, especially with motion artifact or poor contact
• A “possible AF” notification requires confirmation with medical-grade ECG
• These devices cannot detect all arrhythmias and may miss brief episodes

Approach:

Device shows “irregular rhythm” or “possible AF”:

1. Obtain 12-lead ECG in office (or review device ECG if available)
2. If ECG confirms AF: manage as new AF (rate control, CHA₂DS₂-VASc, anticoagulation)
3. If ECG is normal/sinus: consider event monitor if symptoms present; reassure if asymptomatic with normal ECG
4. Single notification without symptoms in low-risk patient: reassurance, repeat ECG if recurs

Device shows “low heart rate” or “high heart rate”:

• Correlate with symptoms and in-office vitals
• Asymptomatic bradycardia on device often artifact; confirm with ECG
• Persistent tachycardia notifications warrant evaluation for underlying cause

Documentation: Note device type, what notification said, and your clinical correlation. “Patient reports Apple Watch notification of ‘irregular rhythm’ on [date]. In-office ECG today shows [findings].”

Electrolyte optimization for ectopy#

When to check and optimize:

• Frequent PVCs/PACs (>1% burden or symptomatic)
• Patients on diuretics, especially loop diuretics
• Patients with heart failure, CKD, or on multiple medications affecting electrolytes

Targets:

• Potassium: 4.0–5.0 mEq/L (higher end of normal reduces ectopy)
• Magnesium: >2.0 mg/dL (often low even with normal K; supplement if <2.0 or symptomatic ectopy)

Supplementation:

• KCl 10–20 mEq daily if K 3.5–4.0 and symptomatic ectopy
• Magnesium oxide 400–800 mg daily or magnesium glycinate 200–400 mg daily if Mg <2.0 or borderline with symptoms
• Recheck levels 1–2 weeks after starting supplementation

Exercise guidance by arrhythmia type#

General guidance: Most patients with benign arrhythmias can and should exercise. Exercise intolerance or exertional symptoms warrant further evaluation before clearance.

Follow-up#

• Benign ectopy, reassurance only: PRN; return if symptoms change or worsen
• Started on rate control for AF: 2–4 weeks to assess HR and symptoms
• Pending monitoring (Holter, event monitor): schedule follow-up to review results
• Cardiology referral placed: ensure appointment scheduled; provide interim guidance

Return precautions (all patients):

• Palpitations with passing out or nearly passing out
• Palpitations with chest pain or shortness of breath
• Palpitations lasting >15–30 minutes without stopping
• New symptoms: leg swelling, worsening exercise tolerance

Patient instructions#

• If you feel your heart racing and also feel faint, have chest pain, or can’t breathe, call 911.
• For brief “skipped beats” that last only seconds and don’t cause other symptoms, these are usually harmless.
• Reduce caffeine, alcohol, and energy drinks—these are common triggers.
• Get enough sleep and manage stress; both affect heart rhythm.
• If your doctor prescribed a heart monitor, wear it as directed and press the button when you feel symptoms.
• Keep a log of when palpitations happen, what you were doing, and how long they lasted.

Smartphrase snippets#

• Palpitations, benign ectopy: Brief "skipped beats," no syncope, no chest pain, no dyspnea. Normal ECG, no structural heart disease. Likely PACs/PVCs. Reassurance provided. Trigger avoidance discussed. Return precautions given.

• Palpitations, monitoring ordered: Intermittent palpitations, [duration/frequency]. No red flags. ECG shows [findings]. Ordered [Holter/event monitor/Zio patch] to capture rhythm during symptoms. Follow-up scheduled to review results.

• Atrial fibrillation, new diagnosis: Irregularly irregular rhythm confirmed on ECG. CHA₂DS₂-VASc score [X]. Started [rate control agent]. [Anticoagulation decision and rationale]. Cardiology referral placed. Discussed stroke risk, medication adherence, and return precautions.

Coding/billing notes#

• Document symptom characteristics (duration, frequency, triggers, associated symptoms)
• Document cardiac risk factors and family history
• If not ordering monitoring, document rationale (e.g., “infrequent, brief, no red flags, normal ECG—monitoring unlikely to capture and low pretest probability of significant arrhythmia”)
• For AF: document CHA₂DS₂-VASc score and anticoagulation decision rationale

Common ICD-10 codes:

• R00.2 — Palpitations
• I49.9 — Cardiac arrhythmia, unspecified
• I49.3 — Ventricular premature depolarization (PVCs)
• I49.1 — Atrial premature depolarization (PACs)
• I48.91 — Unspecified atrial fibrillation
• I48.92 — Unspecified atrial flutter
• I47.1 — Supraventricular tachycardia
• R00.0 — Tachycardia, unspecified (sinus tachycardia)
• F41.0 — Panic disorder (if anxiety-related)

Related pages#

Problem pages:

• Atrial Fibrillation — comprehensive AF management including rate vs rhythm control, anticoagulation decisions, and lifestyle modification
• Generalized Anxiety Disorder — chronic anxiety management when palpitations are anxiety-related

Complaint pages:

• Chest Pain — palpitations with chest pain may indicate ACS or other cardiac pathology
• Syncope — palpitations with syncope require urgent arrhythmia evaluation
• Dyspnea on Exertion — palpitations with dyspnea may indicate heart failure or significant arrhythmia